Welcome to our dedicated page for Structure Therapeutics ADR news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics ADR stock.
Structure Therapeutics Inc. (NASDAQ: GPCR) is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity. News about Structure Therapeutics often centers on progress in its GPCR-targeted pipeline, including clinical trial updates, preclinical data presentations, and capital markets activities related to its development programs.
Investors and observers following GPCR news can expect regular updates on aleniglipron (GSBR-1290), the company’s investigational once-daily oral small molecule GLP-1 receptor agonist. Press releases have covered topline Phase 2b and exploratory study results in people living with obesity or overweight with weight-related comorbidities, details of the ACCESS and ACCESS II clinical programs, body composition and maintenance switching studies, and plans for potential Phase 3 development.
Another frequent news theme is the company’s amylin receptor agonist portfolio, including ACCG-2671 and ACCG-3535. Structure Therapeutics has announced initiation of a first-in-human Phase 1 clinical study of ACCG-2671 for obesity, as well as late-breaking poster presentations showing preclinical data on weight loss and combination effects with GLP-1 receptor agonists. Updates also include disclosures about its broader oral metabolic franchise, such as GIPR, GCGR and APJR programs, and the LPA1R program for idiopathic pulmonary fibrosis.
In addition, GPCR news items include quarterly financial results, business updates, and information on public offerings of American Depositary Shares and pre-funded warrants conducted under an automatic shelf registration statement on Form S-3. Coverage may also highlight participation in healthcare investor conferences and outcomes of annual shareholder meetings. Readers interested in Structure Therapeutics news can use this page to track clinical milestones, financing transactions, and other corporate developments disclosed through press releases and SEC-related announcements.
Structure Therapeutics announced positive topline data from its Phase 2a study and capsule to tablet PK study for its oral GLP-1 receptor agonist, GSBR-1290. The Phase 2a study showed a statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks, while the capsule to tablet PK study achieved up to a 6.9% weight loss. GSBR-1290 demonstrated favorable safety and tolerability with low discontinuation rates due to adverse events.
The company plans to start a 36-week Phase 2b study in the fourth quarter of 2024, following an IND submission to the FDA in the third quarter. The new study will use the tablet formulation and involve approximately 300 participants.
These results underscore the potential of GSBR-1290 as a treatment for obesity, with benefits including once-daily dosing and favorable safety profiles. Future development plans include exploring higher doses and combination therapies.
Structure Therapeutics Inc., a biopharmaceutical company, reported financial results for Q1 2024, highlighting upcoming milestones such as data release for obesity drug GSBR-1290 and plans for Phase 2b study. The company aims to address obesity epidemic with its oral small molecule GLP-1 receptor agonist. Positive financial highlights include a cash position of $436.4 million, funding projected operations through 2026.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.